Consolidated Health Economic Evaluation Reporting Standards: Turkish Adaptation of the Consolidated Health Economic Evaluation Reporting Standards Checklist

SAYGIN AVŞAR, Tuba; YİĞİT, Vahit; YİĞİT, Arzu; ARI, Hakan Oğuz; TECİRLİ, Gülcan; DİLMAÇ, Elife; HUSEREAU, Donald

doi:10.5336/healthsci.2023-96248

Turkiye Klinikleri J Health Sci

2023

DOI: 10.5336/healthsci.2023-96248

|View full text |Cite

Consolidated Health Economic Evaluation Reporting Standards: Turkish Adaptation of the Consolidated Health Economic Evaluation Reporting Standards Checklist

Tuba SAYGIN AVŞAR,

Vahit YİĞİT,

Arzu YİĞİT

et al.

Abstract: ÖZET Amaç: Türkiye'de sağlık ekonomisi ve sağlık teknolojileri değerlendirme (STD) faaliyetlerinin gelişmesine karşın, yapılan yayımlarda raporlama açısından ciddi farklılıklar bulunmaktadır. Bunun sebeplerinden biri de yaygın olarak kabul gören raporlama kritelerinin bulunmayışıdır. Bu çalışma, Konsolide Sağlık Ekonomisi Değerlendirme Raporlama Standartları [Consolidated Health Economic Evaluation Reporting Standards (CHEERS)] kriterlerinin Türkçeye kazandırılmasını amaçlamıştır. Gereç ve Yöntemler: Uyarlama … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?

Yiğit

Kalender

Cetinturk

2023

Cost Eff Resour Alloc

View full text Add to dashboard Cite

Background Alzheimer's Disease (AD), the most common type of dementia, is a chronic, progressive, and neurodegenerative brain discomfort that causes the be damage to brain cells. Although there is no definitive treatment for AD, various drug treatments are used to reduce and control the symptoms of the disease. Developed for the treatment of mild-stage Alzheimer's patients, Aducanumab is the only drug approved by the Food and Drug Administration (FDA) in the past two decades. However, the cost is very high and, in many countries, Aducanumab has not been approved due to insufficient clinical efficacy and lack of evidence yet. This study aims to analyze the cost-effectiveness of Aducanumab, which was developed for the treatment of mild-stage AD, from the patient's perspective. Methods In the study, the Markov model was developed to determine the cost-effectiveness of Aducanumab compared to Standard of Care (SoC) therapy over a 5-year horizon. Cost and effectiveness data were taken from the literature. In the study, the discount rate was determined as 6%. The results were presented as the incremental cost-effectiveness ratio (ICER), which represents the cost per quality-adjusted life years (QALY). The results were retested with a one-way and probabilistic sensitivity analysis (PSA) due to possible uncertainties in the research parameters. The results were presented with the tornado diagram and the scatter plots. Results With the Markov model, the total costs of Aducanumab and SoC treatments over a 5-year horizon were found to be 98.068 $ and 21.292 $, respectively. Aducanumab treatment had an incremental gain of 0.64 QALY and an incremental cost of 76.776 $ compared to the SoC treatment. The ICER value, which shows the additional cost per QALY of Aducanumab, was 119.408 $/QALY. As a result of the study, it was determined that Aducanumab was not cost-effective when compared to SoC treatment. Sensitivity analysis results showed stability against uncertainties. Aducanumab was confirmed not to be cost-effective with its current price and potential clinical benefit. Conclusion The result of the research is considered important in terms of providing evidence-based information on the cost-effectiveness of Aducanumab in Turkey. However, further, research is needed to evaluate Aducanumab's clinical efficacy and cost-effectiveness.

show abstract

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?

Yiğit

Kalender

Cetinturk

2023

Cost Eff Resour Alloc

View full text Add to dashboard Cite

show abstract

Development of A Country Specific Economic Evaluation Methodological Guideline: A Pharmaceutical Application for Turkiye

SONSUZ,

USLU,

AYDIN

2023

Sosyal Güvenlik Dergisi

View full text Add to dashboard Cite

Artan sağlık harcamaları karşısında en fazla faydayı en uygun maliyetle ve toplumun kabul edeceği yollarla sağlamak bu alandaki karar vericilerin en önemli gündemlerinden birisidir. Bu soruna yönelik bir çözüm olarak gündeme gelen STD yaklaşımının önkoşullarından birisi ilaca özgü klinik ve ekonomik değerlendirmeleri içeren başvuru kılavuzlarının olmasıdır. Çeşitli sağlık teknolojileri için oluşturulabilen bu kılavuzlar ilaç alanında olunca, “farmakoekonomik değerlendirme kılavuzu” adını almaktadır. Her ülkenin kendi dinamiklerine göre oluşturulması gereken bu kılavuz örneği Türkiye için bulunmamaktadır. Bu kapsamda bu araştırmanın amacı Türkiye koşullarına özgü bir “Farmakoekonomik Değerlendirme Kılavuzu” önerisinde bulunmaktır. Doküman analizi yöntemi ile verilerini toplayan nitel tasarımlı bu araştırmada verilerin analizinde tümdengelimsel yöntem benimsenmiştir. Öneri kılavuz 14 ana başlıktan oluşmuştur. Kılavuzun bir özeti olarak kabul edilebilecek referans örnekte; SGK’nın (Sosyal Güvenlik Kurumu) perspektifi kabul edilmiştir. Maliyet etkililik ve minimizasyon analizlerinin yapılması, karşılaştırıcı olarak rutin klinik bakımın seçilmesi, maliyetlerde doğrudan tıbbi harcamaların hesaba katılması, sağlık sonucunun kazanılan yaşam yılları cinsinden gösterilmesi, belirsizlik için olasılıksal duyarlılık analizinin ve modellemenin yapılması, hedef nüfus ve alt grupların klinik dosya ile uyumlu tanımlanması ve maliyet/sonuçlarda %3’lük indirgeme yapılması önerilmiştir. Kılavuzda ayrıca bütçe etki analizinin yapılması ve bu analizde 3 yıllık bir etkinin gösterimi istenilmektedir.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Consolidated Health Economic Evaluation Reporting Standards: Turkish Adaptation of the Consolidated Health Economic Evaluation Reporting Standards Checklist

Cited by 2 publications

References 13 publications

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?

Development of A Country Specific Economic Evaluation Methodological Guideline: A Pharmaceutical Application for Turkiye

Contact Info

Product

Resources

About